Treatment of CVD

CV disease causes significant worldwide morbidity and mortality and contributes to substantial health care spending. 

The treatment of hypercholesterolemia, and specifically elevated LDL-C, represents an established strategy to diminish incident CV events and mortality. 

Numerous studies have established the continuous, graded, benefit conferred by LDL-C reduction on CV event risk and mortality. 

Future studies should focus on the impact and safety of targeting “very-low” LDL-C, earlier initiation of LDL-C–lowering interventions, the development and impact of novel therapeutic agents, as well as the use of evidence-based policy and regulatory initiatives to reduce environmental causes of elevated LDL-C on a population level.

READ THE WHOLE STUDY